Cargando…

Alitretinoin in Dermatology—An Update

Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other...

Descripción completa

Detalles Bibliográficos
Autor principal: Bubna, Aditya Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601442/
https://www.ncbi.nlm.nih.gov/pubmed/26538721
http://dx.doi.org/10.4103/0019-5154.164426
_version_ 1782394552192073728
author Bubna, Aditya Kumar
author_facet Bubna, Aditya Kumar
author_sort Bubna, Aditya Kumar
collection PubMed
description Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders.
format Online
Article
Text
id pubmed-4601442
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-46014422015-11-04 Alitretinoin in Dermatology—An Update Bubna, Aditya Kumar Indian J Dermatol E-IJD Resident's Page Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi's sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4601442/ /pubmed/26538721 http://dx.doi.org/10.4103/0019-5154.164426 Text en Copyright: © Indian Journal of Dermatology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle E-IJD Resident's Page
Bubna, Aditya Kumar
Alitretinoin in Dermatology—An Update
title Alitretinoin in Dermatology—An Update
title_full Alitretinoin in Dermatology—An Update
title_fullStr Alitretinoin in Dermatology—An Update
title_full_unstemmed Alitretinoin in Dermatology—An Update
title_short Alitretinoin in Dermatology—An Update
title_sort alitretinoin in dermatology—an update
topic E-IJD Resident's Page
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601442/
https://www.ncbi.nlm.nih.gov/pubmed/26538721
http://dx.doi.org/10.4103/0019-5154.164426
work_keys_str_mv AT bubnaadityakumar alitretinoinindermatologyanupdate